The controversy surrounding Mylan's EpiPen pricing suggests drugmakers have been slow to adapt to an environment in which millions of Americans must pay thousands of dollars out of pocket before their coverage kicks in.
U.S. Sen. Joe Manchin remained mum Wednesday as a pharmaceutical company run by his daughter faced mounting criticism for hiking prices on life-saving allergy injection pens.
Healthcare group purchasing and services company Premier reported a slight decrease in fourth-quarter profit due to severance-related costs in its data software and consulting division.
A new study warns that American operating rooms may be relying too much on medical-device salespeople for technical assistance and that loyalty between surgeons and representatives may contribute to rising hospital costs.
The price of naloxone, a drug used to reverse the effects of an opioid overdose, has skyrocketed in the past few years, according to an analysis by Truven Health Analytics, a research and data firm owned by IBM Corp.
Premier will become the preferred group purchasing organization for the 275 hospitals that comprise America's Essential Hospitals.
The expansion of a group purchasing organization serving the public health sector and the recent launch of similar organizations reflect new demands from providers who are faced with an increasingly consolidated GPO market, experts say.
Shareholders at McKesson's annual meeting sided with the board and management in rejecting proposals to require greater disclosure of political contributions and limit golden parachutes for senior executives in a change of ownership.
The helium shortage is no more—thanks to a device using some duct tape, plastic piping, a folding table and some other decidedly low-tech components.
Research suggests there may be gender, racial and socio-economic disparities when it comes to robotic surgery.
The heads of the CMS and the Food and Drug Administration want universal health insurance claims forms to include unique device identifiers. The UDI would improve post-market surveillance and provide for better value-based reimbursement based on device performance, they say.
The Food and Drug Administration has made strides in preventing new drug shortages but the agency is still struggling to address the glut of ongoing deficits, the GAO says.